



# 2023 Annual Report

# Table Of Contents

**01** Message from Director

**02** Who are we

**03** Our Institutional Partners

**04** Registry

**05** Research

**06** Source Data Verification

**07** Education & Training: Nursing Webinars

**08** Training of Data Entry Operators

**09** Patient Advocacy Group

**10** 3rd Annual Meet

**11** Financial Report

**12** Connect with us

# MESSAGE FROM DIRECTOR

Dear Friends, Colleagues, and Partners,

As we reflect on the past year at the Hematology Cancer Consortium (HCC), we are filled with a profound sense of accomplishment and gratitude. Our mission to enhance the care outcomes of hematological malignancies through collaborative research, data aggregation, and education has seen significant progress and heartening success.

In 2023, we expanded our partnership network from 12 to 30 leading cancer centers across India, a testament to the growing trust and collaboration among the nation's best. Our registries have amassed extensive data that is critical for understanding and improving patient outcomes across various hematological cancers. We remain focused on maintaining the highest quality of this data through rigorous source data verification processes, ensuring its accuracy and reliability.

Our commitment to education has strengthened, with our nursing webinars and data entry operator training programs playing a crucial role in refining the skills necessary to handle complex data and patient care. These initiatives are pivotal in maintaining the integrity and quality of our data, which is fundamental to our research outcomes.

This year, we presented four significant studies at the 65th ASH Annual Meeting, showcasing our leadership in addressing complex challenges in hematological malignancies. These studies have not only advanced our understanding but have also positioned HCC as a leader in the field, influencing treatment protocols and patient care globally.

We also marked our 3rd Annual Meeting with a focus on “Consolidation and Planning for the Future.” This gathering was pivotal, setting the direction for our upcoming initiatives and reinforcing our commitment to structured, impactful research.

Our Patient Advocacy Group has been a beacon of support, organizing monthly meetings that provide essential information and community for patients, survivors, and caregivers. The introduction of online support groups has further extended our reach, ensuring that no one faces their journey alone.

Looking ahead, our goals are clear. We will continue to expand our research, enhance our educational initiatives, and grow our community. The upcoming clinical trials and ongoing studies are set to further our mission, promising another year of significant contributions to the field of hematological cancers.

I am grateful to each one of you—our partners, members, and supporters—for your unwavering support and dedication. Together, we are making a measurable difference in the lives of many. Here’s to continuing our journey with hope, determination, and a shared vision of transforming patient care in hematology.

Thank you for being a part of this remarkable journey.

Warm regards,

**DR. VIKRAM MATHEWS**

**DIRECTOR,**

**HEMATOLOGY CANCER CONSORTIUM- ASSOCIATION**

# WHO ARE WE

Hematology Cancer Consortium (HCC) is a multi center collaborative organization established to fulfil the long felt need of good quality, cooperative group data in hematological malignancies in India.

## OUR GOALS



- Aggregate clinical data to support and advance care outcomes of hematological malignancies
- Develop evidence based, locally relevant treatment protocols and guidelines
- Run investigator initiated prospective collaborative clinical trials addressing regionally relevant questions and evaluating cost effective treatment strategies
- Continuous education to improve awareness and enhance knowledge of therapeutic options for standardization of care in hematological cancers
- Provide information on disease characteristics, disease types and burden of disease, treatment patterns, unique challenges in treatment, short and mid-term outcomes, and long-term effects (outcomes of registry).



# OUR INSTITUTIONAL PARTNERS

We began with 12 leading Cancer Centers as our institutional partner and we currently have 30 partners.



Embrace Good Health

# REGISTRY

One of our goal is to aggregate clinical data to support and advance care outcomes of hematological malignancies.

## Registries:

Registry	Total Records
Acute Myeloid Leukemia	6836
Acute Lymphocytic Leukemia	5553
Chronic Myeloid Leukemia	3578
Acute Promyelocytic Leukemia	813
Lymphoma	9451

We are focusing on understanding existing challenges and developing appropriate solutions.



Providing a brief overview of the records for each registry in 2023, along with the progress in terms of year-wise data contributions from various centers across the country since 2018.



## Acute Myeloid Leukemia (AML) Registry

In the year 2023, twenty eight centers across the country recorded 1607 Acute Myeloid Leukemia patients' information.



### Progress of AML registry from 2018-2023



## Acute Lymphoblastic Leukemia (ALL) Registry

Twenty five centers across the country recorded 1225 Acute Lymphocytic Leukemia patients' information.

### Progress of ALL registry from 2018-2023







## Chronic Myeloid Leukemia (CML) Registry

Twenty nine centers across the country recorded 1259 Chronic Myeloid Leukemia patients' information.



### Progress of CML from 2020-2023



## Acute Promyelocytic Leukemia (APML) Registry

Twenty-one centers across the country recorded 186 Acute Promyelocytic Leukemia patients' information.



### Progress of APML registry from 2018-2023



## Lymphoma (LYM) Registry

Twenty nine centers across the country recorded 3264 Lymphoma patients' information.

### Progress of Lymphoma registry from 2020-2023



# RESEARCH

**Study Title: A phase III randomized study to compare a risk-stratified and response adapted strategy to ABVD regimen in adolescents and adults with advanced stage Hodgkin lymphoma (ABVD Hodgkin's Study)**

**Study design:** Open-label, Phase III randomized study, comparison of two standard-of-care approaches, multi-centre

**Sample size:** 200 patients

**Study duration:** 4 years accrual, 3 years follow-up since the last patient is enrolled and 10 years for the long-term follow-up phase since last patient is enrolled

**CTRI Registration:** CTRI/2020/12/030132

**Status:** 167 patients have been recruited in total. 165 in TMH and 2 in JIPMER.

**Study Title: Outcomes and prognostic factors in patients with Primary Mediastinal B cell Lymphoma: Real world data (PMBCL Study)**

**Study Design:** Observational, retrospective cohort

**Time Perspective:** All the consecutive patients registered between 2015-2020 with diagnosis of Primary Mediastinal B cell Lymphoma

**Status:** Completed

**Outcome:** This large Indian dataset shows that DA-R-EPOCH efficacy is inferior to the NCI trial and North American analysis, with CR at the end of treatment being the key outcome determinant, while selection bias remains a major limitation.

**(Outcomes and prognostic factors in patients with Primary Mediastinal B cell Lymphoma: An experience from HCC, 65th ASH Annual Meeting, 2023)**

**<https://www.hemecancer.org/pdf/abstracts/pmbcl-study.pdf>**

**Study Title: To study outcomes in young CML treated with Tyrosine Kinase Inhibitors (TKI) in India (HCC CML STOUT)**

**Study Design:** Observational, retrospective cohort

**Time Perspective:** Adolescents and young adults (aged 15-29 years) diagnosed with CML in India between January 2015 and 31st March 2022

**Status:** Completed

**Outcome:** The AYA group had fewer low-risk cases hence more number were treated upfront with second-generation TKI and EFS was better in this group, however the registry's short follow-up duration and limited evaluable patients hindered molecular and cytogenetic response analysis.

(To study outcomes in young CML treated with TKI. A registry data from Hematological Cancer Consortium (HCC) of India, 65th ASH Annual Meeting, 2023)

<https://www.hemecancer.org/pdf/abstracts/cml-stout-study.pdf>

**Study Title: Mixed phenotypic acute leukemia- Clinical presentation and outcomes of patients treated with Acute Lymphoblastic Leukemia like protocols a multi-institutional study from India (MPAL Study)**

**Study Design:** Observational, multicentre, prospective cohort study

**Time Perspective:** All consecutive diagnosed with mixed phenotypic acute leukemia (MPAL) between January 2018 and 31st March 2022.

**Status:** Completed

**Outcome:** This study, one of the largest on MPAL patients in a resource-limited setting, found a 10% induction mortality, with worse 2-year EFS and OS likely due to limited access to Allo-HSCT and treatment abandonment.

(Mixed phenotypic acute leukemia- clinical presentation, prognosis and outcomes of patients treated with ALL like protocols- a multi-institutional study from India, 65th ASH Meeting, 2023)

<https://www.hemecancer.org/pdf/abstracts/mpal-study.pdf>

**Study Title: Patterns of care and outcome in Adult and Young Adult (AYA) lymphomas- A multicentre registry study from India (AYA Study)**

**Study Design:** Observational, multicentre, prospective registry study

**Time Perspective:** All consecutive adolescents and young adult cases (15 to 30 years of age) of lymphoma patients registered between January 2017 to December 2022 who had received at least one cycle of chemotherapy

**Status:** Completed

**Outcome:** This large real-world dataset on AYA lymphoma from India highlights a predominance of Hodgkin lymphoma, high radiation use, and adult-type regimens, setting a benchmark for future collaborative studies.

**(Patterns of care and outcome in AYA lymphomas- A multicentre registry study from India, 65th ASH Annual Meeting, 2023).**

<https://www.hemecancer.org/pdf/abstracts/aya-study.pdf>

**Study Title: Outcomes of Philadelphia chromosome positive Acute Lymphoblastic Leukemia (Ph+ ALL): Analysis from the database of the Hematology Cancer Consortium (Ph+ ALL Study)**

**Study Design:** Observational, multicentre, retrospective cohort

**Time Perspective:** All consecutive patients registered between January 2015 and December 2021 with Ph+ ALL as defined by the demonstration of t(9;22) in the baseline conventional karyotype or FISH or the demonstration of BCR-ABL transcript at the time of diagnosis

**Status:** Completed

**Outcome:** In a large prospective study across 12 centers, it was found that most adult Ph+ALL patients in India are treated with pediatric-type protocols, with Dasatinib as the preferred TKI, but there is a high rate of treatment abandonment, including 18% loss to follow-up within six months.

**(Outcomes of Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia: An Indian Multi-Institution, Prospective Study from the Haematology Cancer Consortium (HCC), 65th ASH Online Publication, 2023)**

<https://www.hemecancer.org/pdf/abstracts/ph-all-study.pdf>

## UPCOMING CLINICAL TRIAL

**Study Title:** Phase III open labeled randomized controlled study to evaluate the optimal dose of all-trans retinoic acid in the treatment of low and intermediate risk acute promyelocytic leukemia. (HCC-APL22 DOSA Study)

**Study design:** Phase III open labeled Randomized Control Trial

**Sample size:** 280 patients (140 patients in each arm)

Study duration: 3 years

**Objective:** To evaluate the net treatment benefit (event-free survival, documented infections, differentiation syndrome, hepatotoxicity and neuropathy in decreasing order) between the two study arms.

**Indication:** Patient newly diagnosed with Acute Promyelocytic Leukemia and age more than 15 years at diagnosis.

**Update:** 5 centers have been finalized for the study- Christian Medical College, Vellore; Tata Memorial Hospital, Mumbai; Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry; Malabar Cancer Center, Thalassery; Army Hospital Research and Referral, Delhi. All the study documents have been finalised and funding is under process

# SOURCE DATA VERIFICATION

Source Data Verification (SDV) is a critical process in clinical research that ensures the accuracy and reliability of data collected during clinical trials. It involves comparing data entered into case report forms (CRFs) or electronic data capture systems with the original source records, such as medical charts or laboratory reports. This verification process helps identify and correct discrepancies, ensuring that the data is accurate, complete, and in compliance with Good Clinical Practice (GCP) guidelines. Effective SDV not only enhances data integrity but also contributes to the overall credibility and reliability of the clinical study outcomes.

We started the SDV process from November 2022 and so far we have completed the SDVs of five studies and all the registries.

For the year 2023, we have completed the SDVs of the four studies selected for the 64th ASH annual meeting along with SDVs of all the registries for 7 centers.



# EDUCATION & TRAINING

## NURSING WEBINARS

The HCC nurses group had initiated an education program to enhance knowledge. First nursing webinar was conducted on 27 April 2021.

Twenty-six webinars have been conducted so far. Webinars are held on the last Tuesday of every month. More than 100 nurses participate in these webinars.

Thank you, team!

Nursing Webinars conducted since January-2023:

Topics	Speakers
Care of Neutropenic patients	Ms. Aswathy Asokan, MSc Nursing (PhD), Pan India Nurse Educator, BMT- Hematology department, HCG Group of Hospitals, India
Basics of nutrition in pediatric oncology for Nurses	Ms. Momi Barman, BBCL, Guwahati and Ms. Nikita Gaonkar, CTC, Mumbai, Pediatric Onco Nutritionist, Cuddles Foundation
Oncologic Emergencies: Recognition and Initial Management	Ms. Ratnaprabha Pilane, Senior Nurse, Department of Infection Control, Tata Memorial Hospital, Mumbai
Roles of Nurses in Apheresis	Mrs. Josephine Suganya, Apheresis Nurse, Department of Hematology, CMC Vellore

<b>CAR-T Cell Therapy: Role of Nurses</b>	<b>Mr. Pramodkumar Palavilayil, Nursing Officer, Tata Memorial Hospital, Mumbai</b>
<b>Total Parenteral Nutrition: Clinical, Competencies &amp; Challenges: Nursing Perspective</b>	<b>Ms. Mita Rowchowdhury, Nursing Superintendent, Ranchi Cancer Hospital and Research Centre (RCHRC, Ranchi)</b>
<b>Management of Febrile Neutropenia</b>	<b>Ms. Archana Mehta, Nursing Officer, BSc Nursing, Department of Nursing, Postgraduate Institute of Medical Education &amp; Research, Chandigarh</b>
<b>Nursing Management of children undergoing HSCT</b>	<b>Mr. Bhaskar Kumar S H, Clinical Educator, Mazumdar Shaw Medical Centre, Narayana Health, Bangalore</b>
<b>Infection prevention &amp; control in BMT setting</b>	<b>Mrs. Sangeetha Samuel, , Deputy Nursing Superintendent/Assistant Professor, Christian Medical College &amp; Hospital, Ludhiana, Punjab</b>

**Webinar recordings are available on our website:**

<http://hemecancer.org/>

**Register as a member to access recordings:**

<http://hemecancer.org/webinar-recording.php>

# TRAINING OF DATA ENTRY OPERATORS

We believe in delivering accurate and good-quality data. To encourage this, we have been organizing various training programs for our Data Entry Operators and conducts source data verification as it accrues to ensure the quality of the data generated, provide evidence for the integrity of data at the time of publication and to minimize the missing data.

We conducted DEO training sessions based on the common findings of Source Data Verifications

Topic	Speaker
AML Registry training	Dr Manju Sengar
Training based on common findings from Source Data Verification of HCC Registries	

DEO workshop training program recordings are now available on the HCC website:  
<https://hemecancer.org/training-module.php>

# PATIENT SUPPORT GROUP MEETINGS

We introduced a groundbreaking initiative by establishing a patient advocacy group dedicated to providing unwavering support to both patients and caregivers. The patient support group sessions offer a comprehensive exploration of hematological cancers, featuring insights from leading experts in the field. Each session delves into various aspects of these complex diseases, covering topics such as diagnosis, treatment options, symptom management, and psychosocial support. Through interactive discussions and expert guidance, these sessions foster a sense of empowerment and solidarity among participants, ensuring that no one faces hematological cancer alone.

Seven patient group sessions have been conducted in 2023. Patient Group Sessions are held on third Saturday of every month.

The patient support group sessions commenced since March 2023.

Topic	Speaker
Fuel your body and mind to fight cancer	Dr Gayatri Bhat, Dr Punit Jain, Ms. Rupal Shah and Ms. Mini Menon
Infection control during treatment	Dr Abi Manesh and Ms. Keertibala Shukla
Understanding and Managing side effects of chemotherapy session	Dr Santosh KD and Ms. Mini Menon

<b>Bone Marrow Transplant</b>	<b>Dr Joseph John and Mr. Amit Shenoy</b>
<b>Nutrition during cancer treatment</b>	<b>Ms. Rupal Shah</b>
<b>Treatment of Blood cancer</b>	<b>Dr Manju Sengar</b>
<b>Immunotherapy as a treatment option of blood cancer</b>	<b>Dr Prasanth Ganesan</b>

Patient Support Group Session recordings are now available on the HCC website  
<https://www.hemecancer.org/support-group-meeting.php>

Patient information booklet for hematological cancers are available on the HCC website

English- <https://www.hemecancer.org/patient-education.php>

Hindi- <https://www.hemecancer.org/patient-education-in-hindi.php>

Marathi- <https://www.hemecancer.org/patient-education-in-marathi.php>

Malayalam- <https://www.hemecancer.org/patient-education-in-malayalam.php>

Kannada- <https://www.hemecancer.org/patient-education-in-kannada.php>

# 3RD ANNUAL MEET

Our Third Annual Meeting was conducted in Chennai on 14th October 2023.

The focus of this year meeting was “Consolidation and Planning of Future”.

It was a small meeting comprising of Executive Members.

## Highlights:

- Implementation of Disease Working Group
- Revision of each hematologic cancer Case Record Forms
- Retrospective and Prospective studies planned
- Implementation of new diseases in the registry- Primary Myelofibrosis, Myelodysplastic Syndrome, CAR-T cell therapy





# FINANCIAL REPORT

## Independent Auditor's Report

### M. P. Chitale & Co.

#### Chartered Accountants

Hamam House, Ambalal Doshi Marg, Fort, Mumbai - 400 001 • Tel : 2265 1186 / 2265 3023 / 24 • E-mail : office@mpchitale.com

#### INDEPENDENT AUDITOR'S REPORT

##### To the Members of

##### Hematology Cancer Consortium- Association (HCCA)

##### Report on the Audit of the Financial Statements

##### Opinion

We have audited the financial statements of Hematology Cancer Consortium- Association (hereinafter referred to as "HCCA") ("the Company") having its registered office Shop no. 1A, Ground Floor, Deep Co-operative Housing Society Limited, Jerbai Wadia Road, Parel Bhoiwada, Mumbai, 400012, for the year ended March 31, 2024, which include the Balance Sheet as at that date and the Statement of Income and Expenditure for the period from April 01, 2023 to March 31, 2024 and Cash Flows Statement for the year then ended, and notes to the financial statements, including a summary of significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Companies Act, 2013 in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2024, and its surplus and its cash flows for the year ended on that date.

##### Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

##### Management's Responsibility for the Financial Statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the accounting Standards specified under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls; that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the





financial statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those Board of Directors are also responsible for overseeing the company's financial reporting process.

#### **Auditor's Responsibilities for the Audit of the Financial Statements**

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or taken together, they could reasonably be expected to influence the economic decisions of users taken based on these Standalone financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- i. Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- ii. Consider the internal control relevant to the Company's preparation of the financial statements that give a true and fair view in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on whether the Company has in place an adequate internal financial controls system over financial reporting and the operating effectiveness of such controls.
- iii. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- iv. Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.



- v. Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide management with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

#### Report on Other Legal and Regulatory Requirements

As required by Section 143(3) of the Act, we report that:

- a) We have sought and obtained all the information and explanations, which to the best of our knowledge and belief were necessary for the purposes of our audit.
- b) In our opinion, proper books of account as required by law have been kept by the Company as far as it appears from our examination of those books.
- c) The Balance Sheet, the Statement of Profit and Loss, and the Cash Flow Statement dealt with by this Report are in agreement with the books of account
- d) In our opinion, the aforesaid standalone financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.
- e) On the basis of the written representations received from the directors as April 1, 2023 taken on record by the Board of Directors, none of the directors is disqualified as on 31 March 2023 from being appointed as a director in terms of Section 164 (2) of the Act.
- f) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
  - i. The Company does not have any pending litigations, which would impact its financial position.
  - ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
  - iii. There were no amounts, which were required to be transferred to the Investor Education and Protection Fund by the Company.
  - iv. The Management has represented that, to the best of its knowledge and belief, as disclosed in the note to the accounts 2(j), no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other person(s) or entity(ies), including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company



M. P. Chitale & Co.  
Chartered Accountants

("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

- v. The Management has represented, that, to the best of its knowledge and belief, as disclosed in the note to the accounts 2(k), no funds have been received by the Company from any person(s) or entity(ies), including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the company shall, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.
- vi. The Company has not declared or paid any dividend during the year and has not proposed final dividend for the year.
- vii. Based on our examination, which included test checks, the Company has used accounting software for maintaining its books of account for the financial year ended 31 March 2024 which has a feature of recording audit trail (edit log) facility and the same has operated throughout the year for all relevant transactions recorded in the Software. Further, during the course of our audit we did not come across any instance of the audit trail feature being tampered with, in respect of accounting software for the period for which the audit trail feature was enabled and operating. As proviso to Rule 3(1) of the Companies (Accounts) Rules, 2014 is applicable from April 1, 2023, reporting under Rule 11 (g) of the Companies (Audit and Auditors) Rules, 2014 on preservation of audit trail as per the statutory requirements for record retention is not applicable for the financial year ended 31 March 2024.

For M. P. Chitale & Co.  
Chartered Accountants  
ICAI FRN: 101851W




Ashutosh Pednekar  
Partner  
ICAI M No.: 041037  
UDIN: 24041037BKEIOT8730  
Place: Mumbai  
Date: September 28, 2024

Z:\USER\HCCA\FY 2023-24\Final Audit report FY 23-24.docx

## Balance sheet as at March 31, 2024

Hematology Cancer Consortium- Association			
Balance Sheet as at March 31, 2024		In ₹ (Hundred Of Rupees )	
Particulars	Note No.	As at 31-Mar-2024	As at 31-Mar-2023
<b>EQUITY AND LIABILITIES</b>			
<b>Sources of Funds</b>			
(a) Corpus fund			-
(b) Reserves and Surplus	1	65,211.69	49,869.22
<b>Current Liabilities</b>			
(a) Other Current Liabilities	2	6,807.96	18,601.35
(b) Short-term provisions	3	29,085.88	2,408.86
<b>Total</b>		<b>1,01,105.53</b>	<b>70,879.43</b>
<b>ASSETS</b>			
<b>Non-Current Assets</b>			
(a) Property, Plant and Equipment	4	3,402.56	3,913.08
(b) Other Non-Current Assets	5	6,304.60	4,855.20
<b>Current Assets</b>			
(a) Cash and Cash Equivalents	6	77,306.85	56,391.25
(b) Short-term loans and advances	7	-	772.64
(c) Other current Asset	8	14,091.52	4,900.00
(d) Preliminary Expenditure		-	47.27
<b>Total</b>		<b>1,01,105.53</b>	<b>70,879.43</b>

Also see accompanying Notes to and forming part of the Financial Statements - Note 12

As per our report attached.

**For M. P. Chitale & Co.**  
Chartered Accountants  
Firm Regn. No.101851W

*Ashutosh Pednekar*  
**Ashutosh Pednekar**  
Partner  
M No.: 041037  
Date: September 28, 2024  
Place: Mumbai



**For and On behalf of the Board**  
**Hematology Cancer Consortium- Association**  
CIN: U85100MH2020NPL335745

*Niyati Sutaria James*  
**Niyati Sutaria James**  
Director  
DIN: 09428177

*Palani Thyagarajan*  
**Palani Thyagarajan**  
Director  
DIN: 09428178

*Bhavisha Sudarshan Sanadhya*  
**Bhavisha Sudarshan Sanadhya**  
Chief Executive Officer  
Date: September 28, 2024  
Place: Mumbai



# Statement of Income and Expenditure for the period ended March 31, 2024

Hematology Cancer Consortium- Association				
Statement of Income and Expenditure for the year ended March 31, 2024				
In ₹ (Hundred Of Rupees )				
SR No	Particulars	Note No.	For The Year Ended On 31-Mar-24	For The Year Ended On 31-Mar-23
I	Donations, Grants & Sponsorships	9	138,265.43	197,653.35
II	Other Income	10	2,105.86	2,619.31
III	<b>TOTAL REVENUE (I + II)</b>		<b>140,371.29</b>	<b>200,272.66</b>
IV	<b>EXPENSES</b>			
	Expenses on Objects of Section 8 Company	11	119,950.41	193,268.98
	Depreciation	4	1,095.52	623.00
	Amortization of preliminary expenses		47.27	47.26
	Administration Expenditure		3,935.62	1,289.48
	<b>TOTAL EXPENSES</b>		<b>125,028.82</b>	<b>195,228.72</b>
V	<b>Surplus Before Tax</b>		<b>15,342.47</b>	<b>5,043.94</b>
VI	<b>Tax Expense</b>		-	-
	Current Tax		-	-
	Deferred Tax		-	-
VII	<b>Surplus for the Period(V-VI)</b>		<b>15,342.47</b>	<b>5,043.94</b>

Also see accompanying Notes to and forming part of the Financial Statements - Note 12

As per our report attached.

**For M. P. Chitale & Co.**  
Chartered Accountants  
Firm Regn. No.101851W

*Ashutosh Pednekar*  
**Ashutosh Pednekar**  
Partner  
M No.: 041037  
Date: September 28, 2024  
Place: Mumbai



**For and On behalf of the Board**  
**Hematology Cancer Consortium- Association**  
CIN: U85100MH2020NPL335745

*Niyali Sutaria James*  
**Niyali Sutaria James**  
Director  
DIN: 09428177

*Palani Thyagarajan*  
**Palani Thyagarajan**  
Director  
DIN: 09428178

*Bhavisha Sudarshan Sanadhya*  
**Bhavisha Sudarshan Sanadhya**  
Chief Executive Officer  
Date: September 28, 2024  
Place: Mumbai





## Cash flow statement

Hematology Cancer Consortium- Association		
<b>Cash Flow Statement</b>		
<b>for the Year ended March 31, 2024</b>		
In ₹ (Hundred Of Rupees )		
Particulars	31-Mar-2024	31-Mar-2023
<b>A. Cash flow from operating activities</b>		
Surplus Before Tax	15,342.47	5,043.94
Adjustments for:		
Amortization Expenses	47.27	-47.26
Depreciation	1,095.52	670.26
<b>Operating cash flows before changes in assets/liabilities</b>	<b>16,485.26</b>	<b>5,666.94</b>
<b>Changes in assets/liabilities</b>		
Increase/(decrease) in other current liabilities	-11,793.39	14,960.52
Increase/(decrease) in short-term provisions	26,677.02	2,108.86
(Increase)/decrease Long-term loans and advances	-	-
(Increase)/decrease in Other Non current Assets	-1,449.40	-3,632.29
(Increase)/decrease in short-term loans and advances and Other Current Account	-8,418.88	-5,097.02
<b>Cash generated from operating activities</b>	<b>21,500.61</b>	<b>14,007.00</b>
<b>Net cash flows generated from operating activities (A)</b>	<b>21,500.61</b>	<b>14,007.00</b>
<b>B. Cash flow from investing activities</b>		
Purchase of Property, Plant and Equipment	-585.00	-2,824.70
<b>Net cash flow generated from investing activities (B)</b>	<b>-585.00</b>	<b>-2,824.70</b>
<b>C. Cash flow from financing activities</b>		
Issue of share capital	-	-
<b>Net cash flow generated from financing activities (C)</b>	<b>-</b>	<b>-</b>
<b>Net increase in cash and cash equivalents (A+B+C)</b>	<b>20,915.61</b>	<b>11,182.30</b>
Cash and Cash Equivalents as at the beginning of the year	56,391.25	45,208.94
<b>Cash and Cash Equivalents as at the end of the year</b>	<b>77,306.85</b>	<b>56,391.25</b>

Also see accompanying Notes to and forming part of the Financial Statements - Note 12

As per our report attached.

For M. P. Chitale & Co.  
Chartered Accountants  
Firm Regn. No.101851W

Ashutosh Pednekar  
Partner  
M No.: 041037  
Date: September 28, 2024  
Place: Mumbai



For and On behalf of the Board  
Hematology Cancer Consortium- Association  
CIN: U85100MH2020NPL335745

Niyati Sutaria James  
Director  
DIN: 09428177  
Date: September 28, 2024  
Place: Mumbai

Pulkit Chyagarajan  
Director  
DIN: 09428178

Bhavisha Sudarshan Sanadhya  
Chief Executive Officer



## Fixed Assets

### Hematology Cancer Consortium- Association

Notes Forming part of the Financial Statements

#### Note 4 -Property, Plant and Equipment

In ₹ (Hundred Of Rupees )

DESCRIPTION	RATE	GROSS BLOCK				DEPRECIATION			NET BLOCK		
		AS ON 01.04.2023	ADDITIONS DURING THE YEAR	SALES/ADJ. DURING THE YEAR	AS ON 31.03.2024	PROVIDED UPTO 31.03.2023	DEDUCTION/ ADJUSTMENT	PROVIDED FOR THE YEAR	TOTAL UPTO 31.03.2024	AS ON 31.03.2024	AS ON 31.03.2023
Furniture	9.50%	2,402.70	-	-	2,402.70	57.72	-	236.90	294.62	2,108.08	2,344.98
Computer	31.67%	2,090.90	585.00	-	2,675.90	921.52	-	778.44	1,699.96	975.94	1,169.38
Equipments	19.00%	422.00	-	-	422.00	23.29	-	80.18	103.47	318.53	398.71
<b>TOTAL (A)</b>		<b>4,915.60</b>	<b>585.00</b>	<b>-</b>	<b>5,500.60</b>	<b>1,002.53</b>	<b>-</b>	<b>1,095.52</b>	<b>2,098.04</b>	<b>3,402.56</b>	<b>3,913.08</b>
PERVIOUS YEAR		2,090.90	2,824.70	-	4,915.60	379.53	-	623.00	1,002.53	3,913.08	1,711.37
<b>TOTAL ASSETS</b>		<b>4,915.60</b>	<b>585.00</b>	<b>-</b>	<b>5,500.60</b>	<b>1,002.53</b>	<b>-</b>	<b>1,095.52</b>	<b>2,098.04</b>	<b>3,402.56</b>	<b>3,913.08</b>



*PM*

NSJ

*BB*





## Schedules / Notes

Hematology Cancer Consortium- Association		
Notes Forming part of the Financial Statements		In ₹ (Hundred Of Rupees )

### Note 1 : Reserves & Surplus

Particular	31-Mar-2024	31-Mar-2023
Opening Balance	49,869.22	44,825.28
Add: Surplus carried over to balance sheet	15,342.47	5,043.94
<b>Total</b>	<b>65,211.69</b>	<b>49,869.22</b>

### Note 2 : Current liabilities

Particular	31-Mar-2024	31-Mar-2023
Sundry Creditors	1.50	95.80
Grant Payable	-	4,500.00
Grant Payable (Unutilized)	6,806.46	14,005.55
<b>Total</b>	<b>6,807.96</b>	<b>18,601.35</b>

### Note 3 : Short-term provisions

Particular	31-Mar-2024	31-Mar-2023
Provision for Expenditure	29,085.88	2,408.86
<b>Total</b>	<b>29,085.88</b>	<b>2,408.86</b>

### Note 5 : Other Non-Current Assets

Particular	31-Mar-2024	31-Mar-2023
TDS Receivable	5,304.60	3,855.20
Rent Deposit	1,000.00	1,000.00
Others	-	-
<b>Total</b>	<b>6,304.60</b>	<b>4,855.20</b>

### Note 6: Cash & Bank Balances

Particular	31-Mar-2024	31-Mar-2023
Bank Balances in Savings Account with HDFC Bank		
Account No. 50100347097089	42,579.82	35,647.74
Account No. 50100392097440	34,727.03	20,743.51
Fixed Deposits	-	-
Interest Accrued on Fixed Deposits	-	-
<b>Total</b>	<b>77,306.85</b>	<b>56,391.25</b>



NSJ

*[Signature]*

*[Signature]*



Hematology Cancer Consortium- Association		
Notes Forming part of the Financial Statements	In ₹ (Hundred Of Rupees )	

**Note 7: Short-term loans and advances**

Particular	31-Mar-2024	31-Mar-2023
Advance to Creditors	-	772.64
<b>Total</b>	<b>-</b>	<b>772.64</b>

**Note 8: Other current Asset**

Particular	31-Mar-2024	31-Mar-2023
Grants & Sponsorships Receivable	13,800.00	4,900.00
Prepaid Expenditure	291.52	-
<b>Total</b>	<b>14,091.52</b>	<b>4,900.00</b>

**Note 9: Donations, Grants & Sponsorships**

Particular	31-Mar-2024	31-Mar-2023
Donation	4,680.00	30.00
Grant	1,33,585.43	93,148.67
Sponsorship	-	1,04,474.68
<b>Total</b>	<b>1,38,265.43</b>	<b>1,97,653.35</b>

**Note 10: Other Income**

Particular	31-Mar-2024	31-Mar-2023
Saving Bank Interest	2,105.86	2,607.92
FDR Interest	-	9.71
Interest on Income tax refund	-	1.68
<b>Total</b>	<b>2,105.86</b>	<b>2,619.31</b>

**Note 11: Expenses on Objects of Section 8 Company**

Particular	31-Mar-2024	31-Mar-2023
Research Activity	1,13,962.97	1,74,183.61
Professional Fees	4,826.20	18,203.01
Insurance	-	528.36
Audit Fee	401.20	354.00
Other Expenditure	760.04	-
<b>Total</b>	<b>1,19,950.41</b>	<b>1,93,268.98</b>



NSJ

P.M.

SS



# Notes forming part of the financial statements as at the year ended March 31st, 2024

**Hematology Cancer Consortium-Association**  
CIN No: U85100MH2020NPL335745  
**NOTES FORMING PART OF THE FINANCIAL STATEMENTS AS AT THE YEAR  
ENDED MARCH 31<sup>st</sup>, 2024**

## Note 12

### 1. Corporate Information:

Hematology Cancer Consortium-Association (the Company) is a private company limited by guarantee registered under section 8 of the Companies Act, 2013. The Company was incorporated on January 09, 2020. Object of the company is to initiate a web based online data collection platform for hematological cancers, bio-banking of samples from cases with hematological cancers in each of the participating centers, analyzing the respective data and plan prospective collaborative studies in the relevant field, facilitating basic scientific research to understand the biology of the disorders, developing common treatment protocols and specific guidelines for management of hematological cancers, disseminating the knowledge and information to the physicians, patients, volunteers and other sections of the society as may be deemed fit, facilitating access to standard care treatment for patients diagnosed with hematological cancers and to do all the related or supportive or ancillary activities with respect to hematological cancers.

### 2. Significant Accounting Policies:

#### a. Basis of Accounting

The financial statements of the Company have been prepared in accordance with the Generally Accepted Accounting Principles in India (Indian GAAP) in compliance with the Accounting Standards prescribed under Section 133 of the Companies Act, 2013 and the relevant provisions of the Companies Act, 2013 ("the 2013 Act"). The financial statements have been prepared on accrual basis under the historical cost convention.

The Company is a Small and Medium size Company (SMC) as defined in the general instructions in respect of Accounting Standards notified under the Companies Act, 2013. Accordingly, the Company has complied with the Accounting Standards as applicable to small and medium size Company.

#### b. Use of Estimates

The preparation of financial statements in conformity with Generally Accepted Accounting Principles require estimates and assumptions to be made that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities on the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates and differences between actual results and estimates are recognized in the periods in which the results are known/materialize.



1 NST



c. **Revenue Recognition**

Donations received towards Hematology Cancer Consortium-Association are considered as income when received. Grants and Sponsorship are recognized as income based on the irrespective contractual terms. Revenue is recognized when it is earned and no significant uncertainty exists as to its realization or collection.

d. **Corpus Funds**

Receipts in the form of voluntary contribution made with a specific direction to be treated as corpus are recognized as Corpus Funds.

e. **Related party transactions**

In ₹ (Hundred Of Rupees )

Description of Relationship	Names of related parties	1-April-2023 to 31-Mar-2024	1-April-2022 to 31-Mar-2023
Key Management Personnel (KMP)	Remuneration to Bhavisha Sanadhya – CEO	19,200.00	12,900.00

f. **Income Tax**

Current tax, if any is the amount of tax payable on the taxable income for the year as determined in accordance with the applicable tax rates and provision of the Income Tax Act, 1961. The Company is registered under section 8 of the Companies Act, 2013. The Company is exempt from the payment of Income tax. No provision for taxation has been made in the accounts in view of the exemption eligible to the Company under Section 11 read with Section 2(15) of the Income tax Act 1961

g. **Provisions, Contingent Liabilities & Contingent Assets**

A provision is recognized when the company has a present legal obligation as a result of past events and it is probable that an out flow of resources will be required to settle the obligation in respect of which a reliable estimate can be made. Provisions (excluding employee benefits) are not discounted to present value and are determined based on best estimate required to settle the obligation at the balance sheet date. These are reviewed at each balance sheet date and adjusted to reflect the current best estimates.

h. **Depreciation**

Depreciation on property, plant and equipment is provided on the straight-line method at the rates reflective of the estimated useful life of the assets estimated by the management.



NSJ



- i. **Utilisation of Borrowed funds and share premium**
  - The Company has not granted any advance/loans or investments or provided guarantee or security or the like to any other person(s) or entities with an understanding, whether recorded in writing or otherwise, to further lend/invest/provide guarantee or security or the like to any other person on behalf of the company.
  - The Company has not received any funds from any person(s) or entities with an understanding, whether recorded in writing or otherwise, that the company shall further lend or invest or provide guarantee or security or the like in any other person on behalf of and identified by such person(s)/entities.
- j. Previous year figures have been regrouped/reclassified wherever necessary, in order to make them comparable.
3. **Details on Benami Property Held**  
No proceedings have been initiated or pending against the Company for holding any benami property under the Benami Transaction (Prohibition) Act, 1988 (45 of 1988).
4. **Borrowing from Banks and Financial Institutions on Security of Current Assets**  
The Company does not have any borrowing facilities taken from Banks or Financial Institution.
5. **Willful Defaulter**  
The Company has not been declared as a willful defaulter by any bank (as defined under the Companies Act, 2013), in accordance with the guidelines on willful defaulter issued by the Reserve Bank of India.
6. **Relationship with Struck Off Companies**  
The Company does not have any transaction with Companies struck off under section 248 of the Companies Act, 2013 or section 560 of the Companies Act, 1956.
7. **Registration of charges or satisfaction with the Registrar of Companies**  
There are no changes or satisfaction yet/pending to be registered with the Registrar of Companies at the end of the year.
8. **Compliance with number of layer Companies**  
The company does not have any subsidiary accordingly compliance with the number of layers prescribed under caluse87 of section 2 of the companies act read with Companies (Restriction on number of Layers) Rule 2017 is not applicable.



NST

BSS





## 9. Financial Ratio

Sr. No.	Ratio	Numerator	Denominator	Current Period	Previous Period	% Variance	Reason for Variance
1	Current Ratio	Current Assets	Current Liabilities	NA	NA		
2	Debt Equity Ratio	Total Debts	Shareholder's Equity	NA	NA		
3	Debt Service Coverage Ratio	Earning available for debt service	Debt Service	NA	NA		
4	Return on Equity (ROE)	Net Profit after taxes- preference Dividend	Average Shareholder's Equity	NA	NA		
5	Inventory Turnover Ratio	Cost of Goods sold or Sales	Average Inventory	NA	NA		
6	Trade Receivables Turnover Ratio	Net Credit Sales	Average Account Receivable	NA	NA		
7	Trade Payables Turnover Ratio	Net Credit Purchase/ Expenses	Average Trade Payable	NA	NA		
8	Net Capital Turnover Ratio	Net Sales	Working Capital	NA	NA		
9	Net Profit Ratio	Net Profit	Net Sales	NA	NA		
10	Return on Capital employed (ROCE)	Earning before Interest and Taxes	Capital Employed	NA	NA		

- Current Ratio = Current Assets / Current Liability
- Debt-equity ratio = Total Debt/ Shareholder's Equity
- Debt service coverage ratio = Earnings available for debt service / Debt Service
- Return on equity ratio = Net Profits after taxes – Preference Dividend (if any) / Average Shareholder's Equity
- Inventory turnover ratio = Cost of goods sold OR sales/ Average Inventory
- Trade receivables turnover ratio = Net Credit Sales/ Average Accounts Receivable  
Average trade debtors = (Opening + Closing)/2
- Trade payables turnover ratio = Net Credit Purchases/ Average Trade Payable
- Net capital turnover ratio = Net Sales/ Average Working Capital
- Net profit ratio = Net Profit / Net Sales



4

NSJ

Pm.

KSS



- Return on capital employed= Earning before interest and taxes / Capital Employed  
Capital Employed = Tangible Net Worth + Total Debt + Deferred Tax Liability
- Return on investment=  $\frac{\{MV(T1) - MV(T0) - \text{Sum } [C(t)]\}}{\{MV(T0) + \text{Sum } [W(t) * C(t)]\}}$

T1 = End of time period

T0 = Beginning of time period

t = Specific date falling between T1 and T0







MV(T1) = Market Value at T1

MV(T0) = Market Value at T0

C(t) = Cash inflow, cash outflow on specific date

W(t) = Weight of the net cash flow (i.e. either net inflow or net outflow) on day 't',  
calculated as  $[T1 - t] / T1$

Since the company is incorporated under section 8 of the companies act, 2013 and it has no commercial activities and borrowings, the above ratios are not applicable.

<p><b>For M. P. Chitale &amp; Co.</b> <b>Chartered Accountants</b> FRN: 101851W</p> <p></p> <p><b>Ashutosh Pednekar</b> <b>Partner</b> <b>M.No: 041037</b> <b>Date: September 28, 2024</b> <b>Place: Mumbai</b></p> <p></p>	<p><b>For and on behalf of the Board of Directors</b></p> <p></p> <p><b>Niyati Sutaria James</b> <b>Director</b> <b>DIN: 09428177</b></p> <p></p> <p><b>Palani Thyagarajan</b> <b>Director</b> <b>DIN: 09428178</b></p> <p></p> <p><b>Bhavisha Sudarshan Sanadhya</b> <b>Chief Executive Officer</b> <b>Date: September 28, 2024</b> <b>Place: Mumbai</b></p> <p></p>
--	---

NSJ





# CONNECT WITH US

HCC is deeply grateful to its individual & corporate supporters for their generosity.

You can join us on:



## CONTACT US

EMAIL: [ADMIN@HEMECANCER.ORG](mailto:ADMIN@HEMECANCER.ORG)